OXLUMO 94.5 mg/0.5mL, solution for injection bottle, 0.5 ml
Active ingredients: LUMASIRAN, LUMASIRAN SODIQUE
Commercialized according to BDPMDispensing in France: Prescription only
Solution for injectionbottle, 0.5 mlsous-cutanée
No current ANSM shortage notice is included
Package details
Original BDPM fields are shown in French.
- Official name
- OXLUMO 94,5 mg/0,5mL, solution injectable
- Pharmaceutical form
- solution injectable
- Route of administration
- sous-cutanée
- Presentation description
- 1 flacon(s) en verre de 0,5 ml
- Marketing authorisation holder
- ALNYLAM NETHERLANDS (PAYS-BAS)
- Reimbursement according to BDPM
- 65%
- Approval for use in healthcare institutions
- oui
- Commercialization declaration date
- 8 Mar 2021
- Prescription and dispensing conditions
- Prescription only
- List I: prescription-only medicine
- Prescribed by a hospital doctor
- Prescribed by specialists only
- Enhanced ANSM monitoring
- No
BDPM identifiers
CIS
66316458CIP73021744CIP133400930217443Composition in BDPM
| Component | Amount per unit | Source type |
|---|---|---|
| LUMASIRANsolution | 94,5 mg · un flacon de 0,5 mL de solution | FT |
| LUMASIRAN SODIQUEsolution | 100 mg · un flacon de 0,5 mL de solution | SA |
Information is based on BDPM data and is for reference only. Consult a doctor before use.
Similar medicines
Similar medicines are listed using the official BDPM catalog. Availability must be checked separately. Consult a doctor or pharmacist before switching medicines.
The current BDPM data does not list similar medicines for this product.